Bridging Science and Strategy: Medical Affairs at the Heart of Omnichannel Engagement

In this video podcast hosted by Pharmaphorum, Editor in Chief Jonah Comstock speaks with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of Clinical and Medical Client Services. They discuss Reverba Global’s approach to true omnichannel patient and physician engagement, giving examples and insights on how they are overcoming the challenges…

|

In this video podcast hosted by Pharmaphorum, Editor in Chief Jonah Comstock speaks with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of Clinical and Medical Client Services.

They discuss Reverba Global’s approach to true omnichannel patient and physician engagement, giving examples and insights on how they are overcoming the challenges and building this new paradigm. Tune in to find out how this approach can help your organisation build better connections with patients and HCPs.

Watch here:Bridging Science and Strategy

The Latest

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…

  • Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
    Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact

    Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…

  • How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease
    How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease

    In rare disease, a missing piece in starting and staying on therapy is often lived perspective. Patients and their care partners may begin rare disease treatment with no peer reference…

See More Insights